MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Anika Therapeutics Operating Cycle 2011-2026 | ANIK
Annual Operating Cycle Anika Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 325 | 296 | 298 | 269 | 353 | 365 | 371 | 340 | 344 | 276 | 267 | 214 | 197 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 371 | 197 | 301 |
Quarterly Operating Cycle Anika Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 200 | 200 | 259 | - | 505 | 547 | 542 | - | - | 319 | 282 | - | 97.2 | 109 | 255 | - | 286 | 292 | 372 | 67.3 | 363 | 321 | 280 | 303 | 408 | 363 | 351 | 348 | 305 | 300 | 348 | 305 | 402 | 383 | 385 | 87.7 | 97.7 | 94.7 | 101 | 64 | 83.4 | 86.3 | 114 | 67.3 | 71 | 59.6 | 48.1 | 80.5 | 96.3 | 82.1 | 120 | 86.6 | 133 | 99.8 | 123 | 85.6 | 85.6 | 97.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 547 | 48.1 | 218 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.63 | -1.22 % | $ 16.5 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
102 | $ 316.2 | -4.28 % | $ 41.4 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Завод ДИОД
DIOD
|
64.6 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
9.78 | - | - | - | Russia |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.89 | - | $ 4.85 M | China |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
167 | - | -13.85 % | $ 16.1 M | USA |
 |
Cerus Corporation
CERS
|
47 | $ 1.8 | -2.7 % | $ 343 M | USA |
 |
AbbVie
ABBV
|
350 | $ 202.28 | -2.11 % | $ 358 B | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.04 | -1.28 % | $ 432 M | USA |
 |
Viela Bio, Inc.
VIE
|
174 | - | - | $ 2.91 B | USA |
 |
Coherus BioSciences
CHRS
|
656 | $ 1.63 | -2.69 % | $ 191 M | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.32 | -2.06 % | $ 992 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.12 | -1.22 % | $ 222 M |  Israel |
 |
Ardelyx
ARDX
|
1.05 K | $ 5.8 | -2.93 % | $ 1.4 B | USA |